VISTIDE TREATMENT FOR RELAPSING CMV RETINITIS IN PATIENTS WITH AIDS

接受治疗艾滋病患者复发性巨细胞病毒视网膜炎

• 批准号: 6122108
• 负责人: BRUCE A BARRON
• 金额: $ 1.12万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-19 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122108
• 关键词: AIDS; antiviral agents; clinical research; cytomegalovirus; eye disorder chemotherapy; human subject; human therapy evaluation; opportunistic infections; relapse /recurrence; retinitis

The Vistide treatment for Relapsing Cytomegalovirus Retinitis in patients with AIDS is a research study designed to: 1) make intravenous Vistide more broadly available to patients with CMV retinitis who cannot tolerate, or have progressed despite treatment with Ganciclovir and/or foscarnet, and 2) gather additional information about the safety and effectiveness of intravenous Vistide in the treatment of relapsing CMV retinitis in patients with AIDS. Patients with AIDS are at high risk for reactivation of CMV. CMV infection may be asymptomatic. However, CMV may progress and cause severe and potentially disabling damage to the lungs, gastrointestinal tract and the retina of the eye.

一项研究旨在：1）使CMV视网膜炎的患者更广泛地使用静脉内vistide的研究，该研究对艾滋病患者的复发性巨细胞病毒性视网膜炎进行了vistide治疗。 艾滋病。 艾滋病患者有CMV重新激活的高风险。 CMV感染可能是无症状的。 但是，CMV可能会进展并可能对肺部，胃肠道和眼睛的视网膜造成严重损害。